Patient Convenience Study (RE-SONANCE)
Patient Convenience Study (RE-SONANCE)
NCT ID: NCT02684981 Phase: Status: COMPLETED Enrollment: 9472 Completion: 2017-06-01
Conditions
Atrial Fibrillation, Stroke
Summary
The aim of this non-interventional study is to describe patient's perception of anticoagulant treatment when using Pradaxa to prevent stroke and systemic embolism while suffering from atrial fibrillation (according to its approved indication in the approved dosages of 110 milligrams or 150 milligrams twice daily) in comparison to standard care using Vitamin K Antagonist (VKA).
Primary Outcome
Convenience PACT-Q2 Scores at Second and Last Assessment Compared to Baseline Assessment